47. Zhang W, Doherty M, Pascual E, et al; EULAR (European League Against Rheumatism) Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Ann Rheum Dis. 2006;65(10):1312-1324.
48. Schlesinger N, Yasothan U, Kirkpatrick P. Pegloticase [published correction appears in Nat Rev Drug Discov. 2011;10(2):156]. Nat Rev Drug Discov. 2011;10(1):17-18.
49. Pascual E, Sivera F, Yasothan U, Kurkpatrick P. Febuxostat. Nat Rev Drug Discov. 2009;8(3): 191-192.
50. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout; the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.
51. Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008;4(6):1209-1220.
52. Reinders MK, Jansen TL. New advances in the treatment of gout: review of pegloticase. Ther Clin Risk Manag. 2010;6:543-550.
53. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci. 2007; 4(2):83-93.
54. Richette P, Brière C, Hoenen-Clavert V, et al. Rasburicase for topaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007;34(10):2093-2098.
55. Moolenburgh JD, Reinders MK, Jansen TL. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol. 2006;25(5):749-752.